Status:

WITHDRAWN

Impact of Statins on Cytokine Expression in Pneumonia

Lead Sponsor:

The University of Texas Health Science Center at San Antonio

Conditions:

Community Acquired Pneumonia

Cardiovascular Risk Factors

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The investigators are conducting a study to determine the effects of a cholesterol-lowering medication, called simvastatin on pneumonia. People in the study will be in the hospital because they have p...

Eligibility Criteria

Inclusion

  • At least 18 years of age,
  • Chart documentation by a clinician of an initial working diagnosis of pneumonia within 24 hours of admission,
  • Chest x-ray or other imaging evidence consistent with pneumonia within 48 hours of hospitalization, and
  • One of the following severity criteria: pneumonia severity index class III or higher, at least 2/5 components of the CURB-65, or ICU level care within 24 hours of admission.
  • Having one Food and Drug Agency approved indication for statin therapy

Exclusion

  • Prior Treatment with one or more doses of a statin within 30-days prior to admission or during the current hospitalization.
  • Hospitalization \> 24 hours at time of the diagnosis of pneumonia.
  • Hospitalization \> 48 hours at time of study enrollment.
  • Residence in a skilled nursing facility.
  • Previously diagnosed human immunodeficiency virus infection with a current CD4 count \< 200 cells/mm.
  • Immunosuppression
  • Patient or family decision to limit medical care ("comfort measures only").
  • Known allergy to statin therapy.
  • Active or planned pregnancy or breastfeeding.
  • Inability to take oral medications at the time of study enrollment.
  • Pre-existing liver disease or AST/ALT \> 10% the upper limit of normal.
  • Creatinine phosphokinase (CPK or CK) \> 50% above the upper limit of normal.
  • Partial ileal bypass.
  • Concurrent treatment with potential interacting drugs: ketoconazole, itraconazole, amiodarone, clarithromycin, erythromycin, cyclosporine, danazol, niacin, protease inhibitors, telithromycin, verapamil, gemfiborzil, ezetimibe (Zetia), nefazodone.
  • Transfer from an outside hospital.

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2011

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00946166

Start Date

July 1 2009

End Date

August 1 2011

Last Update

April 22 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Audie L Murphy Memorial Veterans Hospital

San Antonio, Texas, United States, 78229